We add to these existing data of MMP-9 activity and hemorrhage risk in AIS patients treated with tPA by examining AIS patients with LVO treated with MT, a therapy with much higher reperfusion rates and one which allows the recording of reperfusion status after treatment. The gene discussed is MMP9; the disease is hemorrhage.